The role of the ERN EpiCARE Research Council is to support research conducted by EpiCARE members, with an aim to improve the quality and quantity of research within the network.
Specific goals include:
The EpiCARE Research Council includes EpiCARE’s Coordinator, 4 members of the EpiCARE Steering comittee, the ECET Chair, the Registry representative, the ePAG representatives, a representative of a current joint ERN/European research Initiatives (eg EJP RD, Human Brain Project that provide ressources to the network), the EpiCARE Research projects manager, the EpiCARE data manager and an ILAE representative.
The chair of EpiCARE’s Research Council is Helen Cross, deputy chair is Kees Braun.
An EpiCARE project will be defined as a project that is led by a number of EpiCARE members (at least 2) or from a single centre where data for a study is gathered from other EpiCARE HCP.
The project must be proposed to the research council prior to any funding application, and have undergone a quality check/peer review.
In order for ERN EpiCARE support to be given to a project, a project should be reviewed by the council. On submission, a reviewer will be nominated from the network and advice provided within 2 weeks. A letter will be provided by the Council Chair
Amount: 25 000€ to cover the organization of a 2-days workshop
Deadline: April 25th, 2022
Aim
The goal of the workshops is to train researchers and clinicians affiliated to ERN- Full Members or – Affiliated Partners in relevant topics on research in rare diseases. Training themes may include innovative research methodologies, diagnostic research methodologies, interdisciplinary treatment approaches, such as gene therapy and transplantation, etc. Moreover, the workshops will be aiming to provide a cross-ERN added value.
The workshops will be delivered as two-day events. Topics can be proposed by clinicians/investigators affiliated to ERN-institutions or EJP RD beneficiaries.
Topics
Topics will be selected taking into consideration several elements such as:
Applicants
The workshops selected for funding will be attended only by individuals affiliated to ERN institutions. Participants will be selected by the coordinator of the ERN managing institution and the workshop organizer based on pre-defined criteria. The costs for the workshop organization will be covered up to a limit of € 25.000. These include the costs and fees typically charged by the event venue, administrative, audio-visual and IT facilities essential for the workshop, catering, travel and accommodation expenses of workshops participants and invited speakers (if envisaged).
The applicant submitting workshop topics must fulfil one of the following conditions:
Amount: up to $10,000
Deadline: March 31, 2022
Focus areas: TBC1D24 gene mutation variants, related seizure research, related symptom research; other topics welcome.
The TBC1D24 Foundation, with funding from generous donors, is accepting applications for a total of USD $10,000.00 for scientific and/or clinical research studies related to natural history, treatment and research. Consideration will be given to applicants in the field of neurology, genetics and behavior. Interest and efforts in furthering understanding of the TBC1D24 gene mutation are appreciated and the impact it will have on the families.
The TBC1D24 Foundation 2022 Grant is being established to encourage meritorious
scientific and clinical studies designed to improve the diagnosis or therapy of individuals with a TBC1D24 gene mutation. Proposals that focus on defining the natural history, early detection and diagnosis, or novel treatment strategies will be given priority.
More info
Deadline model: single-stage
Deadline: 21 September 2022 17:00:00 Brussels time
Budget : €38 000 000
Expected Outcome:
Scope:
Building on the EBRAINS architecture and base facilities developed under Horizon 2020, the scope of this action is to:
Enabling the EBRAINS research infrastructure digital facilities supporting neuroscience dedicated tools and services, with a high quality of service including robustness, security, scalability, flexibility, usability and user-centricity. This includes a sustainable system for allocation and management of data capacities and of simulation and computing service resources.
Establishing in-depth collaboration with teams from other European research and testing infrastructures and of EOSC, in order to ensure efficiency and harmonisation, e.g. regarding Authorisation, Authentication and Identification (AAI), Persistent Identifiers (PID), discovery ontologies and API for both services and data.
Directly interfacing with the European HPC capacities towards exascale, deployed in EuroHPC and capitalising on the FENIX[1] developments for big-data integration and interactive use.
Delivering an efficient Europe-wide service to researchers, based on promoting excellence and innovation, and supporting users’ digital experiments with the assistance of high-level support teams and feedback mechanisms, and guiding communities in developing novel software solutions that build on the EBRAINS base offering.
Deploying an open metrics framework to assess the EBRAINS performances reached, the efficiency of the facilities offered in particular regarding the human-based services, and the uptake especially regarding the enabled science excellence and related results and the medical and technological innovation empowerment.
Constantly improving open science services/applications that respond to up-to-date and upcoming identified needs of the neuroscientific community, with a co-design approach and in-depth engagement with scientific, medical and industrial stakeholders and the establishment of an appropriate and transparent prioritisation mechanism. This includes ensuring openness to other research groups and new applications; reaching out to scientific and industrial communities, including with tailored training and skills development programmes.
The deployment of complementary S&T services from regional or national competence nodes, supporting and enriching the cloud-based deliveries and facilitating the sharing of produced data and use of national resources.
In addition to the above, EBRAINS should open its approaches to other communities, going beyond neuroscience, for example by supporting compute-intensive simulation to identify candidate drugs addressing new disease targets in other explicit medical domains where this approach is justified.
Budget: €183 000 000
Deadline model: single-stage
Deadline date: 04 May 2022 17:00:00 Brussels time
Scope
You should apply to this call if you are looking for support from EIC Pathfinder Open to realise an ambitious vision for radically new technology, with potential to create new markets and/or to address global challenges. EIC Pathfinder Open supports early stage development of such future technologies (e.g. various activities at low Technology Readiness Levels 1-4), based on high-risk/high-gain science-towards-technology breakthrough research (including ‘deep-tech’). This research must provide the foundations of the technology you are envisioning.
EIC Pathfinder Open may support your work, especially if it is highly risky: you may set out to try things that will not work; you may be faced with questions that nobody knows the answer to yet; you may realise that there are many aspects of the problem that you do not master. On the contrary, if the path you want to follow is incremental by nature or known, EIC Pathfinder Open will not support you.
Before applying you should verify that your proposal meets all the following essential characteristics (‘Gatekeepers’):
Budget: €131 360 126 (Grants of up to EUR 2.5million)
Deadline model: multiple cut-off
Deadline:
Is intended to meet the following specific objectives:
The starting point in the project should be a preliminary technology or protocol of an RNA-based therapy for complex or rare genetic diseases with unmet medical needs that demonstrates, in a lab or preclinical context, the essential features that underpin the disruptive nature of the innovation. The endpoint in the project should be a completely functional version of the technology suitable for clinical validation, supported by a sound and implementable commercialisation/exploitation strategy.
Proposals are expected to contribute to at least one of the following outcomes:
Budget: €427 276 125 (Per project: 36 months)
Deadline model: single-stage
Deadline: 15 November 2022 17:00:00 Brussels time
Scope: The Doctoral Networks aim to train a new generation of creative entrepreneurial and innovative early-stage researchers, able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit.
For supported doctoral candidates
For participating organizations:
Deadline model: single-stage
Deadline: 14 September 2022 17:00:00 Brussels time
Budget:
Scope: Fellowships will be provided to excellent researchers, undertaking international mobility either to or between EU Member States or Horizon Europe Associated Countries, as well as to non-associated Third Countries. Applications will be made jointly by the researcher and a beneficiary in the academic or non-academic sector.
Postdoctoral Fellowships either can take place in Europe (i.e. in an EU Member State or a Horizon Europe Associated Country) or in a Third Country not associated to Horizon Europe:
Deadline model: single-stage
Deadline: 21 April 2022 17:00:00 Brussels time
Budget : €35 000 000 (around EUR 7.00 million per project)
Scope
Proposals should address all of the following areas:
Deadline model: single-stage
Deadline: 28 April 2022 17:00:00 Brussels time
Link: https://erc.europa.eu/funding/advanced-grants
Budget
Advanced Grants may be awarded up to a maximum of EUR 2 500 000 for a period of 5 years (the maximum award is reduced pro rata temporis for projects of a shorter duration).
However, up to an additional EUR 1 000 000 can be requested in the proposal to cover (a) eligible “start-up” costs for Principal Investigators moving to the EU or an Associated Country from elsewhere as a consequence of receiving the ERC grant and/or (b) the purchase of major equipment and/or (c) access to large facilities and/or (d) other major experimental and field work costs, excluding personnel costs. (As any additional funding is to cover major one-off costs it is not subject to pro-rata temporis reduction for projects of shorter duration. All funding requested is assessed during evaluation).
Objectives
ERC Advanced Grants are designed to support excellent Principal Investigators at the career stage at which they are already established research leaders with a recognised track record of research achievements. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.
Profile of the ERC Advanced Grant Principal Investigator
ERC Advanced Grant Principal Investigators are expected to be active researchers and to have a track record of significant research achievements in the last 10 years which must be presented in the application.
A competitive Advanced Grant Principal Investigator must have already shown a record which identifies them as an exceptional leader in terms of originality and significance of their research contributions.
Principal Investigators of Advanced Grant proposals will be expected to demonstrate a record of achievements appropriate to the field and at least matching one or more of the following benchmarks: 10 publications as main author (or in those fields where alphabetic order of authorship is the norm, joint author) in major international peer-reviewed multidisciplinary scientific journals, and/or in the leading international peer-reviewed journals and peer-reviewed conferences proceedings of their respective field; 3 major research monographs. This benchmark is relevant to research fields where publication of monographs is the norm.
Other alternative benchmarks that may be considered (individually or in combination) as indicative of an exceptional record and recognition in the last 10 years: 5 granted patents; 10 invited presentations in well-established internationally organised conferences and advanced schools; 3 research expeditions led by the applicant Principal Investigator; 3 well-established international conferences or congresses where the applicant was involved as a member of the steering and/or organising committee; International recognition through scientific or artistic prizes/awards or membership in well-regarded Academies or artefact with documented use (for example, architectural or engineering design, methods or tools); Major contributions to launching the careers of outstanding researchers; Recognised leadership in industrial innovation.
Deadline date: December 31, 2022
Budget: €2 000
The Dravet Syndrome Foundation Spain (FSD) Open-Access Support Program is an ongoing call for proposals, and it joins recent research initiatives initiated by FSD, such as the Call for Innovative Research Projects in Advanced Therapies for Dravet Syndrome or the Program for the development of new scientific tools initiated last February 1st together with Tel Aviv University.
This is an ongoing call only limited by FSD’s budget. Authors can apply for a grant of up to EUR 2,000 (approximately $2400 USD) to cover the open-access publishing fees required for the publication in international scientific journals of a manuscript resulting from high quality research on Dravet syndrome.
Budget: $30,000
Deadline:
Link: https://www.curechd2.org/2022grant
Through our Early-Stage Investigator Grant Program, CCC hopes to accelerate the development of therapeutic treatments and disease-modifying advancements for those living with CHD2-related disorders. This grant program is designed to facilitate preliminary investigations that will potentially lay the groundwork for subsequent grants from the government, industry, or other funding sources, including Coalition to Cure CHD2.
CCC is interested in supporting research that advances the understanding of the cellular, molecular, genetic, and systems-level mechanisms of CHD2-related disorders. However, priority will be given to innovative projects, which could potentially lead to therapeutic treatments or a cure for those with CHD2-related disorders.
The Innovative Health Initiative (IHI), a European Union public-private partnership funding health research and innovation, has published draft information on upcoming funding opportunities in 2022 in order to give potential applicants additional time to find or build a consortium and prepare a strong proposal.
The first call for proposals will be launched in the first half of 2022. The following draft themes could be included in the future calls:
Single stage calls
Two stage calls
Please check the IHI website and social media for regular updates related to the upcoming calls.
ders.
Deadline model: single-stage
Planned opening date: 12 January 2022
Deadline date: 21 April 2022 17:00:00 Brussels time
Budget: 30 M€
Type of action: HORIZON-COFUND HORIZON Programme Cofund Actions.
More information
Expected Outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Expected impacts
Proposals for topics under this destination should set out a credible pathway to contributing to tackling diseases and reducing disease burden, and more specifically to several of the following impacts:
Deadline model: single-stage
Planned opening date: 06 October 2021
Deadline date: 21 April 2022 17:00:00 Brussels time
Budget: 60M€ – around 10M€ per project
More information
Expected Outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed, tailored and contributing to all of the following expected outcomes:
Diagnostics industries move towards market approval for companion diagnostics.
Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.
Scope
The applicants should perform the clinical validation of qualified biomarkers (not limited to molecular biomarkers) that will enable the identification of appropriate patients to ensure an effective and efficient use of existing pharmaceuticals in the treatment of major diseases and conditions. The relevant biomarkers should allow providing the right medicinal product, at the right dose and the right time, according to the concept of personalised medicine, taking into account, among others, differences of sex, age, ethnicity and gender identity. This topic refers to medicines that are already on the market and not to the validation of biomarkers for the development of new medicinal products. It addresses broadly prescribed medicines for major diseases and conditions, including but not limited to cardiovascular diseases. A condition is that preliminary studies or publications have demonstrated that the pharmaceuticals considered are efficient in less than 50% of the population treated. This topic excludes cancer and rare disease treatments. The applicants should consider existing guidelines, standards and regulations, as appropriate. Synergies with relevant European Research Infrastructures are encouraged.
Type of action: HORIZON-PCP HORIZON Pre-commercial Procurement
Deadline model: single-stage
Planned opening date: 06 October 2021
Deadline date: 21 April 2022 17:00:00 Brussels time
Budget: 25 M€ – 5 M€ per project
More information
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 4 “Ensuring access to innovative, sustainable and high-quality health care”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:
Scope
Pre-commercial procurement (PCP) can boost innovation in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. Through the competitive development of a range of breakthrough innovations for a concrete health care challenge, PCP can strengthen the security of the supply chain in the health care sector.
Pre-commercial procurement actions in the area of health care gather relevant public and private procurers to address a common, unmet need through the cross-border public and private procurement of research and development for demand-driven innovative solutions. Specific guidance on PCP actions and minimum eligibility requirements can be found in General Annex H[1] of the Horizon Europe work programme.
Proposals should therefore be based on clearly identified user needs and well-structured work plans, explaining how the procured research and development will contribute to the expected outcomes. In addition, proposals should clearly state the expected health benefits of the solutions that will be developed during the course of the action. In this context, applicants should also consider aspects of accessibility and affordability of the solution, efficiency of the technology when implemented in the relevant contexts and how it contributes to health systems resilience.
This topic prioritizes areas of health care such as health promotion, preparedness, prevention, surveillance and rapid response to cross-border health threats. Promoting coordination, cooperation and common standards in the procurement of innovation in health care (including emergency procurement) should be at the heart of any proposal submitted as well as facilitating the digital and green transition of EU health systems.
A wide variety of settings are potentially relevant for the implementation of such innovative solutions, such as: primary health care settings, ambulatory care, hospitals, specialized centres, and long-term health care facilities. The involvement of end-users and the use of cross-sectorial approaches are essential in the area of health.
Within this topic, it is possible to provide for the transfer and adaptation of solutions and/or interventions from other sectors to health care. It is open both to proposals requiring: i) improvements mainly based on one specific solution/technology field; and ii) end-to-end solutions that need combinations of different types of innovation.
Proposals should demonstrate the potential and any future plans for the sustainability of good practices developed or implemented during the action, beyond its life. Such good practices could include cooperation with policy makers to reinforce relevant national policy frameworks, relevant actions to improve the skills of health professionals, patients or carers in the use of the solutions and collaboration with stakeholders for standardization purposes or in order to leverage additional national funds or private investment for procuring solutions.
Synergies with the Technical Support Instrument and the European Structural and Investment Fund are encouraged.
Type of action: HORIZON-PPI HORIZON Public Procurement of Innovative Solutions
Deadline model: single-stage
Planned opening date: 06 October 2021
Deadline date: 21 April 2022 17:00:00 Brussels time
Budget: 15 M€ – 5 M€ per project
More information
Expected Outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 4 “Ensuring access to innovative, sustainable and high-quality health care”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes specified below:
Scope
Public procurement of innovative solutions (PPI) can boost the wider market uptake of high impact innovations in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. This can support the economic recovery of the EU by providing incentives to the EU health and technology industry (especially spin-offs, start-ups and SMEs) to innovate and by providing business opportunities to commercialise innovative products or services at a larger scale than they would normally have.
The actions supported will target critical-scale deployment of relevant health care solutions across different regions in Europe by engaging public and/or private procurers from each participating country (at national, regional or local level) that have deployment responsibilities and budget control in the relevant area of care or supply of services. Procurers will specify, purchase and deploy solutions addressing their relevant, shared unmet needs, while engaging together in a supply and demand side dialogue, in order for the deployed solutions to deliver sustainable, new or improved health care services and outcomes, always taking into account patient feedback.
Proposals should therefore be based on clearly identified user needs and well-structured work plans, explaining how the procurement of the innovative solutions will contribute to the expected outcomes. In addition, proposals should clearly state the benefits of the solutions that will be developed during the course of the project. In this context, applicants should consider aspects of accessibility and affordability of the solution, efficiency of the technology when implemented in the relevant contexts and how it contributes to health systems resilience.
This topic prioritises areas of health care such as health promotion, preparedness, prevention, surveillance and rapid response to cross-border health threats. Promoting coordination, cooperation and common standards in the procurement of innovation in health care (including emergency procurement) should be at the heart of any proposal submitted as well as facilitating the digital and green transition of EU health systems.
Activities covered should include cooperation with policymakers to reinforce the national policy frameworks and mobilise substantial additional national budgets for the PPI, searching support and collaborating with respective coordination and networking projects. Likewise, awareness raising, technical assistance and/or capacity building beyond the project to mainstream PPI implementation and removing obstacles for introducing the innovative solutions to be procured into the market could be included.
A wide variety of settings are potentially relevant for the implementation of such innovative solutions, for example primary health care settings, hospitals, specialised centres, and long-term health care facilities. The involvement of end-users and the use of cross-sectorial approaches are necessary in the area of health. They can lead to more impactful proposals, especially if combined with cost-effectiveness analyses in comparison with the status quo.
Within this topic, it is possible to foresee the transfer and adaptation of solutions and/or interventions from other sectors to health care. It is open both to proposals requiring improvements mainly based on one specific solution/technology field, as well as to proposals requiring end-to-end solutions that need combinations of different types of innovation.
Synergies with the Technical Support Instrument and the European Structural and Investment Fund are encouraged.
Funding for scientific meetings or workshops relevant to neurobiology of epilepsy can also be provided through the NBC. Requests for sponsoring such workshops are considered for funding on an annual basis by the NBC. To apply, please complete the NBC Funding Request Form by 31 July of the year preceding the planned meeting. Decisions on support will be announced by the end of March of the year of the event.
Aims: The first aim of the Networking Support Scheme in the European Joint Programme on Rare Diseases (EJP RD) is to encourage sharing of knowledge on rare diseases or rare cancers between health care professionals, researchers and patients in new or expanding research networks by funding networking events.
The second aim of the Networking Support Scheme is to enable or increase the participation of usually underrepresented countries in Europe in new and in expanding research networks on rare diseases or rare cancers.
Budget: In this Networking Support Scheme applicants can apply for a budget of a maximum of 30,000 € per event.
Focus of the Networking events: The scheme will provide financial support to applicants to organize workshops or conferences. These workshops or conferences are meant to:
The focus of these workshops or conferences should be (the implications of) research results and innovative solutions. The results of these networking events may lead to future collaborative and novel research efforts.
Requirements: at least one Principal applicant and two co-applicants from three different countries mentioned above have to apply together for support of a Networking event.
Dates: the Call for the NSS is open on a continuous basis. Events may be organized between 6 and 18 months after the application date for 2021. From 2022 onwards, events may be organized between 6 and 12 months after the application date.
The next applications will be collected on December 2, 2021 at 14.00 (CET)
The applications will be collected on the following preliminary dates in 2022.
March 1, 2022 at 14.00 (CEST)
September 1, 2022 at 14.00 (CEST)
December 1, 2022 at 14.00 (CET).
You can sign up below to receive the EpiCARE Research Calls Newsletters, sent a few times a year, to inform about the new research calls:
Menu
Funding
The ERN EpiCARE was created in 2017 and is co-funded by the European Union.
EpiCARE © 2021 all rights reserved | Privacy Policy | Webdesign : Marc Chaperon
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-advertisement | 1 year | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Cookie | Duration | Description |
---|---|---|
YSC | session | This cookies is set by Youtube and is used to track the views of embedded videos. |
Cookie | Duration | Description |
---|---|---|
_ga | 2 years | This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors. |
Cookie | Duration | Description |
---|---|---|
IDE | 1 year 24 days | Used by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile. |
NID | 6 months | This cookie is used to a profile based on user's interest and display personalized ads to the users. |
test_cookie | 15 minutes | This cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies. |
VISITOR_INFO1_LIVE | 5 months 27 days | This cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website. |
Cookie | Duration | Description |
---|---|---|
_ga_K3WGJ1B9KB | 2 years | No description |
CONSENT | 16 years 7 months 7 days 16 hours 17 minutes | No description |